Every Form 4 that Pliant Therapeutics, Inc. (PLRX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PLRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PLRX filings page.
PLIANT THERAPEUTICS, INC. director Robert Iannone received a grant of 60,000 stock options on July 9, 2026. The options have an exercise price of $1.13 per share and are exercisable for common stock until July 9, 2036. According to the vesting terms, 1/36th of the options vest in substantially equal monthly installments on each monthly anniversary of July 9, 2026, conditioned on Iannone’s continuous service to the company.
PLIANT THERAPEUTICS, INC. director Flavia Borellini received a compensatory stock option grant covering 60,000 shares of common stock on July 9, 2026. The option has an exercise price of $1.13 per share and expires on July 9, 2036. Vesting occurs as 1/36th of the option each month starting on July 9, 2026, subject to her continued service, and all 60,000 option shares are reported as held directly after the award.
Pliant Therapeutics director Gayle A. Crowell received a compensation grant of stock options. The award covers 70,000 options to buy Pliant Therapeutics common stock at an exercise price of $1.14 per share, expiring on June 11, 2036.
According to the vesting schedule, 25% of the options vest on October 1, 2026, another 25% on January 1, 2027, and another 25% on April 1, 2027. The remaining 25% vest on the earlier of the one-year anniversary of the June 11, 2026 grant date or the next annual meeting of stockholders, subject to Crowell’s continued service as a director.
Pliant Therapeutics director Thomas A. McCourt received a grant of stock options covering 70,000 shares of common stock. The options have an exercise price of $1.14 per share and expire on June 11, 2036.
These options were granted as compensation and do not represent an open-market purchase. According to the vesting schedule, 25% of the options vest on each of October 1, 2026, January 1, 2027, and April 1, 2027, with the remaining 25% vesting on the earlier of the one-year anniversary of the grant date or the next annual stockholder meeting, subject to McCourt’s continued service on the board.
Pliant Therapeutics director Steve E. Krognes received a compensation-related stock option grant. He was awarded options to purchase 70,000 shares of Pliant Therapeutics common stock at an exercise price of $1.14 per share, expiring on June 11, 2036.
According to the vesting schedule, 25% of the option vests and becomes exercisable on each of October 1, 2026, January 1, 2027, and April 1, 2027. The remaining 25% vests on the earlier of the one-year anniversary of the June 11, 2026 grant date or the next annual meeting of stockholders, provided he continues to serve as a director through the applicable dates.
Pliant Therapeutics director John T. Curnutte received a grant of stock options covering 70,000 shares of common stock. The options carry an exercise price of $1.14 per share and expire on June 11, 2036, giving him the right to buy shares at that price in the future.
According to the vesting schedule, 25% of the options vest on each of October 1, 2026, January 1, 2027, and April 1, 2027, with the remaining 25% vesting on the earlier of the one-year anniversary of the June 11, 2026 grant date or the next annual stockholder meeting, subject to his continued service as a director.
PLIANT THERAPEUTICS director Hoyoung Huh received a new stock option grant for 70,000 shares of common stock. The option has a $1.14 per share exercise price and expires on June 11, 2036. This is a compensation-related award, not an open-market trade.
According to the vesting schedule, 25% of the option becomes exercisable on each of October 1, 2026, January 1, 2027, and April 1, 2027. The remaining 25% vests on the earlier of the one-year anniversary of the June 11, 2026 grant date or the next annual stockholder meeting, contingent on continued board service.
PLIANT THERAPEUTICS, INC. director Darren S. Cline received a grant of stock options covering 70,000 shares of common stock. The options carry an exercise price of $1.14 per share and expire on June 11, 2036.
These options were granted as compensation rather than bought in the open market. According to the vesting schedule, 25% of the options vest and become exercisable on each of October 1, 2026, January 1, 2027, and April 1, 2027, with the remaining 25% vesting on the earlier of the one-year anniversary of the June 11, 2026 grant date or the next annual meeting of stockholders, subject to his continued service as a director. Following this grant, he holds options for 70,000 shares directly.
Pliant Therapeutics, Inc. Chief Operating Officer Minnie Kuo reported an option repricing affecting her existing stock options. On the April 17, 2026 effective date, she surrendered options covering 150,000, 40,000 and 55,200 shares of common stock with exercise prices of $16.18, $17.44 and $11.14, respectively, and received new options for the same share amounts at an exercise price of $1.33 per share.
The board approved this company‑wide repricing on April 15, 2026 for options granted on or before March 1, 2025, and all other terms, including vesting under the 2020 and 2022 plans, remain unchanged. The repriced awards may revert to their original exercise prices if exercised during an eighteen‑month “Retention Period” starting on the effective date, or if Kuo is terminated for cause or resigns (other than for good reason) before that period ends, subject to the detailed conditions described.
PLIANT THERAPEUTICS, INC. Chief Financial Officer Keith Lamont Cummings reported an option repricing approved by the board on April 17, 2026. Existing stock options granted on or before March 1, 2025 were cancelled and replaced, share-for-share, with new options at an exercise price of $1.33 per share.
The repriced options keep their original vesting schedules and updated expiration dates as previously reported. During a defined Retention Period starting April 17, 2026, any repriced option exercised will revert to its original higher exercise price, and the options can also revert if certain termination or resignation conditions occur.
Pliant Therapeutics President and CEO Bernard Coulie reported an option repricing affecting several existing stock option grants. On the April 17, 2026 effective date, multiple options covering common stock were surrendered to the issuer and regranted with a new exercise price of $1.33 per share, replacing higher original exercise prices such as $34.65 and $26.50. The board approved this repricing for options granted on or before March 1, 2025, with all other terms unchanged.
The repriced options will revert to their original exercise prices if exercised during an eighteen‑month Retention Period starting April 17, 2026, or upon certain termination or resignation events described in the CEO’s severance plan. Several option expiration dates were also corrected, including updates to January 24, 2029 and March 31, 2030.
PLIANT THERAPEUTICS, INC. granted its Chief Human Resource Officer, Lily Cheung, a series of repriced stock options as part of a board-approved option repricing effective April 17, 2026. Existing options covering 123,000, 52,000 and 51,750 shares of common stock, previously struck at $21.935, $17.44 and $11.14 per share, were surrendered back to the company and replaced with new options over the same share amounts at an exercise price of $1.33 per share, the closing price on the effective date.
All other terms of the options, including vesting under the company’s 2020 Stock Option and Incentive Plan, remain unchanged. The repriced options can revert to their original exercise prices if exercised during a defined Retention Period or if Cheung’s employment ends under certain conditions, and a prior expiration date has been corrected to January 19, 2033.
Pliant Therapeutics reported that its Chief Financial Officer, Keith Lamont Cummings, received a new stock option grant. The option allows him to buy 400,000 shares of common stock at an exercise price of $1.30 per share, expiring on January 22, 2036. According to the vesting terms, 1/48th of the shares vest and become exercisable on each monthly anniversary of January 1, 2026, as long as he continues to serve the company. After this award, he holds 400,000 stock options directly.
Pliant Therapeutics, Inc. reported that its Chief Operating Officer, Minnie Kuo, received a stock option grant for 300,000 shares of common stock. The option has an exercise price of $1.30 per share and was granted on January 22, 2026, with an expiration date of January 22, 2036. No purchase price was paid for the grant itself.
According to the vesting terms, 1/48th of the option vests and becomes exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2026, as long as Kuo continues to provide service to the company on each vesting date. After vesting, the option allows her to buy Pliant common shares at the fixed exercise price within the option term.
Pliant Therapeutics granted its Chief Human Resource Officer, Lily Cheung, a stock option on January 22, 2026. The option gives her the right to buy 300,000 shares of common stock at an exercise price of $1.30 per share, expiring on January 22, 2036.
According to the vesting terms, 1/48th of the option vests in substantially equal monthly installments on each monthly anniversary of January 1, 2026, as long as she continues serving the company. After this grant, she directly holds 300,000 stock options.
Pliant Therapeutics President and CEO Bernard Coulie received a grant of stock options covering 1,230,000 shares of common stock on January 22, 2026. The options have an exercise price of $1.30 per share and are held directly. According to the vesting terms, 1/48th of the shares subject to the option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2026, contingent on his continued service with the company.
Pliant Therapeutics’ Chief Financial Officer Keith Lamont Cummings reported an automatic sale of company stock. On January 20, 2026, a plan sold 24,002 shares of Common Stock on his behalf at a weighted average price of $1.28 per share, as part of a nondiscretionary Rule 10b5-1 arrangement.
The shares were sold by a broker over a price range of $1.245 to $1.33 between January 20 and January 22, 2026, to cover withholding taxes related to the vesting of previously granted restricted stock units. After this transaction, Cummings beneficially owned 297,214 shares of Pliant Therapeutics Common Stock, which include 1,958 shares acquired through an employee stock purchase plan.
Pliant Therapeutics Chief Human Resource Officer Lily Cheung reported a sale of company stock under a tax-withholding plan. On January 20, 2026, a company plan sold 7,534 shares of Common Stock on her behalf at a weighted-average price of $1.28 per share, in transactions intended to comply with Rule 10b5-1. The sales were executed between $1.245 and $1.33 over several days to cover withholding taxes tied to the vesting of previously granted restricted stock units.
After these transactions, Cheung beneficially owned 44,847 shares of Pliant Therapeutics Common Stock. This total includes 1,956 shares acquired through an Employee Stock Purchase Plan program, showing she continues to hold a meaningful equity position in the company.
Pliant Therapeutics President and CEO Bernard Coulie reported a sale of 89,375 shares of common stock on January 20, 2026 at a weighted average price of $1.28 per share. The filing explains this was a nondiscretionary sale under a plan intended to satisfy Rule 10b5-1, executed by a broker between prices of $1.245 and $1.33 to cover withholding taxes tied to vesting restricted stock units.
After this transaction, Coulie directly beneficially owns 505,601 shares of common stock, which include 1,959 shares acquired through an employee stock purchase program. He is also reported as indirectly owning 409,317 shares held by The Coulie/Leyman Family Trust, where he and his spouse serve as trustees; he disclaims beneficial ownership of those shares beyond his pecuniary interest.
Pliant Therapeutics, Inc. Chief Operating Officer Minnie Kuo had 6,917 shares of common stock sold on January 20, 2026 at a price of $1.28 per share. This was a nondiscretionary sale by a plan under Rule 10b5-1, carried out by a broker as part of transactions at prices ranging from $1.245 to $1.33 between January 20 and January 22, 2026. The sales were made on behalf of a group of employees, including Kuo, to cover withholding taxes related to the vesting of previously granted restricted stock units. After this transaction, Kuo beneficially owned 37,806 shares of Pliant Therapeutics common stock directly.